Merck Sharp & Dohme LLC
Coformulated favezelimab/pembrolizumab
Metastatic Urothelial Carcinoma
Countdown
328days
Phase 2 readout · May 31, 2027
What's at stake
Phase 2 trial results for Coformulated favezelimab/pembrolizumab in Metastatic Urothelial Carcinoma are due May 31, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT05845814: Phase 2 trial, sponsor Merck Sharp & Dohme LLC, drug Coformulated favezelimab/pembrolizumab. Primary completion date 2027-05-31 (estimated).”